The effectiveness, side effects and acceptability of locally available brand of Clopidogrel (Osvix) as antiplatelet tablet in CABG patients
Background: Platelet activation and aggregation plays an essential role in the for-mation of coronary artery thrombosis. Nowadays, the Clopidogrel is administered oral-ly as an inhibitor of platelet aggregation. Due to the high price of the original brand of Clopidogrel (Plavix), an Iranian brand of...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | fas |
| Published: |
Tehran University of Medical Sciences
2014-07-01
|
| Series: | Tehran University Medical Journal |
| Subjects: | |
| Online Access: | http://tumj.tums.ac.ir/browse.php?a_code=A-10-25-5216&slc_lang=en&sid=1 |
| _version_ | 1818145323109842944 |
|---|---|
| author | Behzad Imani Reza Safi-Ariyan Babak Manaafi Arezo Karampourian Karim Ghazikhanlou Sani |
| author_facet | Behzad Imani Reza Safi-Ariyan Babak Manaafi Arezo Karampourian Karim Ghazikhanlou Sani |
| author_sort | Behzad Imani |
| collection | DOAJ |
| description | Background: Platelet activation and aggregation plays an essential role in the for-mation of coronary artery thrombosis. Nowadays, the Clopidogrel is administered oral-ly as an inhibitor of platelet aggregation. Due to the high price of the original brand of Clopidogrel (Plavix), an Iranian brand of Clopidogrel (Osvix) has been produced. This study was conducted to evaluate the effectiveness, side effects and acceptability of lo-cally available brand of Osvix as anti platelet tablet in coronary artery bypass grafting patients in comparison to the original brand (Plavix) by means of platelet aggregation indexes.
Methods: This clinical study, was conducted at Heart Center of Ekbatan university Hospital in Hamadan in October 2011 to May 2012. In this study 80 patients undergo-ing coronary artery bypass grafting (CABG) were participated in two independent treatment groups. One group used the Iranian brand of Osvix and other one used the original brand (Plavix) as an inhibitor of platelet aggregation. To evaluate the effective-ness of these two in-inhibiting platelets regimens, blood samples were taken from the patients and platelet aggregation test was performed using Helena Biosiences Europe, PACKS4 aggrigometry system (made in France).
Results: Mean platelet-rich plasma amount for the Osvix and Plavix treatment group was 236.260 and 153.290 plt/µl respectively. Results showed a statistically significant difference in the rate of platelet-rich plasma by two above mentioned treatment groups. There was no observed statistical difference in side effects of two studied treatment groups. It must be noted that the effectiveness of Plavix tablet regimen as a platelet aggregation inhibitor in patients undergoing CABG was higher than the Osvix tablet treatment regimen.
Conclusion: This study showed the Iranian brand of Clopidogrel (Osvix) is significantly different from the original brand (Plavix) in terms of performance factors in preventing platelet aggregation in patients undergoing coronary artery bypass grafting. |
| first_indexed | 2024-12-11T12:01:38Z |
| format | Article |
| id | doaj.art-0eb70ee9bf6148a9a05a20fead98ecec |
| institution | Directory Open Access Journal |
| issn | 1683-1764 1735-7322 |
| language | fas |
| last_indexed | 2024-12-11T12:01:38Z |
| publishDate | 2014-07-01 |
| publisher | Tehran University of Medical Sciences |
| record_format | Article |
| series | Tehran University Medical Journal |
| spelling | doaj.art-0eb70ee9bf6148a9a05a20fead98ecec2022-12-22T01:08:03ZfasTehran University of Medical SciencesTehran University Medical Journal1683-17641735-73222014-07-01724207214The effectiveness, side effects and acceptability of locally available brand of Clopidogrel (Osvix) as antiplatelet tablet in CABG patientsBehzad Imani 0Reza Safi-Ariyan 1Babak Manaafi 2Arezo Karampourian 3Karim Ghazikhanlou Sani 4 Department of Operating Room, Hamedan University of Medical Sciences, Hamedan, Iran. Department of Heart Surgery, Hamedan University of Medical Sciences, Hamedan, Iran. Department of Heart Surgery, Hamedan University of Medical Sciences, Hamedan, Iran. Department of Medical- Surgical, Hamedan University of Medical Sciences, Hamedan, Iran. Department of Radiology, Ha-medan University of Medical Sciences, Hamedan, Iran. Background: Platelet activation and aggregation plays an essential role in the for-mation of coronary artery thrombosis. Nowadays, the Clopidogrel is administered oral-ly as an inhibitor of platelet aggregation. Due to the high price of the original brand of Clopidogrel (Plavix), an Iranian brand of Clopidogrel (Osvix) has been produced. This study was conducted to evaluate the effectiveness, side effects and acceptability of lo-cally available brand of Osvix as anti platelet tablet in coronary artery bypass grafting patients in comparison to the original brand (Plavix) by means of platelet aggregation indexes. Methods: This clinical study, was conducted at Heart Center of Ekbatan university Hospital in Hamadan in October 2011 to May 2012. In this study 80 patients undergo-ing coronary artery bypass grafting (CABG) were participated in two independent treatment groups. One group used the Iranian brand of Osvix and other one used the original brand (Plavix) as an inhibitor of platelet aggregation. To evaluate the effective-ness of these two in-inhibiting platelets regimens, blood samples were taken from the patients and platelet aggregation test was performed using Helena Biosiences Europe, PACKS4 aggrigometry system (made in France). Results: Mean platelet-rich plasma amount for the Osvix and Plavix treatment group was 236.260 and 153.290 plt/µl respectively. Results showed a statistically significant difference in the rate of platelet-rich plasma by two above mentioned treatment groups. There was no observed statistical difference in side effects of two studied treatment groups. It must be noted that the effectiveness of Plavix tablet regimen as a platelet aggregation inhibitor in patients undergoing CABG was higher than the Osvix tablet treatment regimen. Conclusion: This study showed the Iranian brand of Clopidogrel (Osvix) is significantly different from the original brand (Plavix) in terms of performance factors in preventing platelet aggregation in patients undergoing coronary artery bypass grafting.http://tumj.tums.ac.ir/browse.php?a_code=A-10-25-5216&slc_lang=en&sid=1clopidogrel coronary artery bypass platelet aggregation |
| spellingShingle | Behzad Imani Reza Safi-Ariyan Babak Manaafi Arezo Karampourian Karim Ghazikhanlou Sani The effectiveness, side effects and acceptability of locally available brand of Clopidogrel (Osvix) as antiplatelet tablet in CABG patients Tehran University Medical Journal clopidogrel coronary artery bypass platelet aggregation |
| title | The effectiveness, side effects and acceptability of locally available brand of Clopidogrel (Osvix) as antiplatelet tablet in CABG patients |
| title_full | The effectiveness, side effects and acceptability of locally available brand of Clopidogrel (Osvix) as antiplatelet tablet in CABG patients |
| title_fullStr | The effectiveness, side effects and acceptability of locally available brand of Clopidogrel (Osvix) as antiplatelet tablet in CABG patients |
| title_full_unstemmed | The effectiveness, side effects and acceptability of locally available brand of Clopidogrel (Osvix) as antiplatelet tablet in CABG patients |
| title_short | The effectiveness, side effects and acceptability of locally available brand of Clopidogrel (Osvix) as antiplatelet tablet in CABG patients |
| title_sort | effectiveness side effects and acceptability of locally available brand of clopidogrel osvix as antiplatelet tablet in cabg patients |
| topic | clopidogrel coronary artery bypass platelet aggregation |
| url | http://tumj.tums.ac.ir/browse.php?a_code=A-10-25-5216&slc_lang=en&sid=1 |
| work_keys_str_mv | AT behzadimani theeffectivenesssideeffectsandacceptabilityoflocallyavailablebrandofclopidogrelosvixasantiplatelettabletincabgpatients AT rezasafiariyan theeffectivenesssideeffectsandacceptabilityoflocallyavailablebrandofclopidogrelosvixasantiplatelettabletincabgpatients AT babakmanaafi theeffectivenesssideeffectsandacceptabilityoflocallyavailablebrandofclopidogrelosvixasantiplatelettabletincabgpatients AT arezokarampourian theeffectivenesssideeffectsandacceptabilityoflocallyavailablebrandofclopidogrelosvixasantiplatelettabletincabgpatients AT karimghazikhanlousani theeffectivenesssideeffectsandacceptabilityoflocallyavailablebrandofclopidogrelosvixasantiplatelettabletincabgpatients AT behzadimani effectivenesssideeffectsandacceptabilityoflocallyavailablebrandofclopidogrelosvixasantiplatelettabletincabgpatients AT rezasafiariyan effectivenesssideeffectsandacceptabilityoflocallyavailablebrandofclopidogrelosvixasantiplatelettabletincabgpatients AT babakmanaafi effectivenesssideeffectsandacceptabilityoflocallyavailablebrandofclopidogrelosvixasantiplatelettabletincabgpatients AT arezokarampourian effectivenesssideeffectsandacceptabilityoflocallyavailablebrandofclopidogrelosvixasantiplatelettabletincabgpatients AT karimghazikhanlousani effectivenesssideeffectsandacceptabilityoflocallyavailablebrandofclopidogrelosvixasantiplatelettabletincabgpatients |